Miscellaneous hematological agents:
Indications for: MOZOBIL
In combination with granulocyte colony stimulating factor (G-CSF): To mobilize hematopoietic stem cells to the peripheral blood for collection and autologous transplantation in patients with non-Hodgkin's lymphoma or multiple myeloma.
Adult Dosage:
Start after 4 days' treatment with G-CSF. Give by SC inj approx.11hrs before starting apheresis. Repeat up to 4 consecutive days. Base dose on actual body weight. ≤83kg: 20mg fixed dose or 0.24mg/kg once daily; >83kg: 0.24mg/kg once daily. Max 40mg/day. Renal impairment (CrCl≤50mL/min): ≤83kg: 13mg or 0.16mg/kg once daily; >83–<160kg: 0.16mg/kg once daily; max 27mg/day.
Children Dosage:
Not established.
MOZOBIL Warnings/Precautions:
Not for use in leukemia. May cause mobilization of tumor cells (in combination with G-CSF). Monitor blood and platelet counts. Monitor for splenic enlargement/rupture after administration in combination with G-CSF; evaluate if left upper abdominal pain and/or scapular or shoulder pain occurs. Monitor for signs/symptoms of hypersensitivity during and after administration for at least 30mins. Have anaphylactic treatment readily available. Moderate to severe renal impairment. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 1 week after last dose. Pregnancy: avoid; exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after last dose).
MOZOBIL Classification:
Hematopoietic stem cell mobilizer.
MOZOBIL Interactions:
May be potentiated by drugs that reduce renal function or compete for active tubular secretion.
Adverse Reactions:
Diarrhea, nausea, fatigue, inj site reactions, headache, arthralgia, dizziness, vomiting; hypersensitivity reactions (may be serious), tumor cell mobilization, leukocytosis, thrombocytopenia, enlarged spleen, vasovagal reaction may occur.
Generic Drug Availability:
NO
How Supplied:
Single-dose vial (1.2mL)—1
